GSK Files Its BCMA Drug In Multiple Myeloma

Filing Underpinned By Good DREAMM-2 results

 
• By Sten Stovall

GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.

Multiple_Myeloma
GSK’s Could Become First Anti-BCMA Agent Approved In US • Source: Shutterstock

More from Business

More from Scrip